Measles: Recognition and Referral
How to recognise suspected measles at the pharmacy counter, when to isolate and refer, and your operational responsibilities as a pharmacist when a notifiable disease is suspected.
Why this matters
Measles is one of the most infectious diseases known, with a reproduction number of 12 to 18 in an unvaccinated population.1 It spreads through airborne respiratory particles and can remain a risk in poorly ventilated indoor spaces. An infectious person can contaminate the air in a pharmacy for up to two hours after leaving. Treating suspected measles as a simple viral illness risks exposing unvaccinated, immunocompromised, pregnant, and infant contacts in the pharmacy environment.
UK measles notifications have increased significantly since 2023, driven by gaps in MMR-containing vaccine coverage that accumulated during the COVID-19 pandemic.2 The pharmacist is often the first healthcare contact for a child or adult presenting with fever and rash. Two doses of an MMR-containing vaccine provide approximately 99% protection; anyone who is unvaccinated or has received only one dose is genuinely at risk.1
Measles is a notifiable disease in England.3 Registered medical practitioners have the statutory duty to notify all suspected cases to the regional health protection team (HPT) by telephone within 24 hours. In practice, clinicians across healthcare settings should notify or seek advice from the HPT when measles is suspected. Community pharmacists should follow their local standard operating procedure, ensure the patient's GP is informed before the patient attends any healthcare setting, and contact the HPT directly where local protocols indicate this. Reporting routes and legal frameworks differ across the UK: this article describes the England pathway. Pharmacists in Scotland, Wales, and Northern Ireland should follow their national health protection notification route and local SOP.
Red flags vs More likely benign
| Feature | More likely benign | Red flag ⚠ |
|---|---|---|
| Rash pattern | Non-specific viral rash, scattered, no clear spread direction | Maculopapular rash starting at hairline and face, spreading cephalocaudal (head to toe) over 3 days with concurrent fever above 38.5 degrees C |
| Eyes | Mild seasonal watering or mild allergy | Significant bilateral conjunctivitis with redness, watering, and photophobia alongside rash and fever |
| Cough | Mild dry cough with upper respiratory tract infection | Harsh persistent cough with stridor (croup) or any respiratory distress suggesting pneumonia |
| Consciousness | Tired but rousable, irritable but responsive | Drowsy, confused, difficult to rouse, or seizures (suggestive of measles encephalitis) |
| Breathing | Comfortable at rest, breathing unlaboured | Fast breathing, visible chest recession, grunting, or cyanosis (measles pneumonia) |
| Vaccination history | Two confirmed doses of an MMR-containing vaccine received | Unvaccinated, single dose only, or vaccination history unknown |
Think Measles if Your Patient Says...
The combination of high fever, red eyes, and a rash starting on the face in an unvaccinated patient is measles until proven otherwise.
- "He had a really high temperature for four or five days and now there is a rash on his face and it is spreading down his body."
- "Her eyes are very red and she keeps saying the light hurts - she has this rash coming out on her face."
- "She has not had her MMR - we never got around to it when she was small."
- "There has been measles going around his school and now he has got a rash and a terrible cough."
- "He started with what looked like a really bad cold last week, now he has a red rash on his face and chest."
- "I came in for something for my eyes and my temperature - I have been unwell since my friend told me she had measles."
If you hear any of these phrases alongside fever and rash, move the patient away from the waiting area immediately and call the GP surgery to arrange same-day assessment. Do not direct the patient to attend any healthcare setting without telephoning ahead first.
🛑 MEASLES: Recognition and Action Framework
Use at the counter whenever a patient presents with fever and rash of uncertain cause.
Ask directly: have you or your child had two doses of MMR or MMRV? Unvaccinated or single-dose status places the patient at genuine risk and increases your index of suspicion significantly. From January 2026 the routine childhood schedule uses MMRV for some age groups; older cohorts may have received MMR.
Ask: has the patient been in contact with a confirmed or suspected measles case in the past 7 to 14 days? Known school or household exposure is a major risk factor.1
Do not allow a patient with suspected measles to wait in the pharmacy waiting area. Move them to a separate, adequately ventilated room or ask them to wait outside. If the consultation room is small and poorly ventilated, asking the patient to wait outside or return home while you arrange telephone referral may reduce exposure risk for others.
Cough, Coryza (runny nose), and Conjunctivitis alongside high fever (above 38.5 degrees C) for 3 or more days form the classic measles prodrome. All three present with a facial rash is highly suspicious.4
The measles rash starts at the hairline and face, then spreads downward to the trunk and limbs over 3 days. On darker skin tones it may be harder to see but remains palpable as a maculopapular texture.
Call 999 if the patient has any of: seizures, altered consciousness, severe breathing difficulty, or collapse. Measles encephalitis and pneumonia are serious complications that require emergency admission.
All patients with suspected measles require same-day GP or urgent care assessment. Call the surgery by telephone before the patient leaves or travels. The surgery needs warning to arrange infection-control measures before the patient arrives. Do not send the patient to any healthcare setting unannounced.6
Do not rely on the absence of rash to exclude measles. The rash appears 3 to 5 days into the illness. A patient is infectious from 4 days before the rash to 4 days after it appears.1
High-Risk Groups, Atypical Presentations, and Pharmacy Actions
These patients face greater complication risk and require the same referral pathway regardless of whether the presentation is classic.
- Infants under 12 months: measles in infants under 12 months carries the highest complication risk. Some residual maternal antibody may be present in the first 6 months but wanes; those born to unvaccinated mothers have no protection.
- Immunocompromised individuals (including those on high-dose corticosteroids, biological therapies, or with haematological malignancy): the rash may be absent or atypical. Pneumonitis and encephalitis risk is significantly higher. Do not offer self-care-only advice to this group.
- Pregnant women: measles in pregnancy carries a risk of preterm labour, miscarriage, and low birth weight. It does not cause congenital abnormalities (unlike rubella), but maternal complications are serious. Refer urgently and alert the obstetric team.
- Adults who received only one dose or were vaccinated before the two-dose schedule was introduced: single-dose efficacy is approximately 95% but breakthrough infection is possible. Do not assume adults are immune on the basis of age alone.
- Koplik spots: white-grey spots on the buccal mucosa (inner cheek) appearing 1 to 2 days before the rash are a characteristic early feature of measles. A pharmacist may observe these if the patient opens their mouth, but their absence does not exclude the diagnosis.4
- Darker skin tones: the classic red maculopapular rash may be less visible. Focus on the distribution (starting at face, spreading downward), palpable texture, and the clinical context.
- Post-exposure contacts: if measles is confirmed or strongly suspected, ask who else in the household is unvaccinated. Unvaccinated contacts may be eligible for post-exposure MMR within 72 hours of exposure, or for human normal immunoglobulin (HNIG) within 6 days. These are arranged through the local HPT, not the pharmacy.5
- Staff exposure and immunity: after a suspected measles case in the pharmacy, document staff and patient exposure details. Identify any staff without evidence of two MMR-containing doses or confirmed measles immunity and seek advice from the HPT or occupational health according to local SOP.7
- Personal protective equipment: if face-to-face assessment is unavoidable, minimise contact time. A surgical mask may reduce large droplet spread if the patient can tolerate it, but measles requires airborne-risk precautions. Staff PPE requirements should follow local infection prevention and control guidance.7
- Documentation: document presenting symptoms, rash onset date, fever history, vaccine status, exposure history, isolation steps taken, who was contacted (GP, HPT, or both), advice given to the patient, and any onward referral or HPT advice received.
After a suspected measles case leaves the pharmacy, keep the room out of use and allow adequate ventilation before it is used again. Follow local infection prevention and control guidance for environmental decontamination.
What to do in pharmacy
Key takeaways
- Move any patient with suspected measles away from the waiting area immediately and call the GP surgery before the patient travels to any healthcare setting.
- The statutory notification duty for measles lies with registered medical practitioners, but community pharmacists should notify or seek advice from the local health protection team by telephone as soon as measles is suspected, in line with local SOP.
- The rash appears 3 to 5 days into the illness: an unvaccinated patient with fever, cough, and red eyes may already be infectious before any rash appears.
📚 References
- UK Health Security Agency. National Measles Guidelines Version 7. London: UKHSA; March 2026. https://www.gov.uk/government/publications/national-measles-guidelines
- UK Health Security Agency. Measles: guidance, data and analysis. London: UKHSA; updated 2024. https://www.gov.uk/government/collections/measles-guidance-data-and-analysis
- UK Health Security Agency. Notifiable diseases and causative organisms: how to report. London: UKHSA; updated 2024. https://www.gov.uk/guidance/notifiable-diseases-and-causative-organisms-how-to-report
- National Institute for Health and Care Excellence. Measles. Clinical Knowledge Summary. London: NICE; updated 2023. https://cks.nice.org.uk/topics/measles/
- UK Health Security Agency. Measles: the green book, chapter 21. London: UKHSA; 2013 (updated 2022). https://www.gov.uk/government/publications/measles-the-green-book-chapter-21
- NHS England. Measles guidance for healthcare services. London: NHS England; 2024. https://www.england.nhs.uk/long-read/measles-guidance-for-healthcare-services/
- NHS England. Guidance for risk assessment and infection prevention and control measures for measles in healthcare settings. London: NHS England; 2024. https://www.england.nhs.uk/long-read/guidance-for-risk-assessment-and-infection-prevention-and-control-measures-for-measles-in-healthcare-settings/
Download the checklist
Disclaimer: For educational use by healthcare professionals only. Does not replace clinical judgement, local pathways, or NICE guidance. Not for public self-diagnosis.